-
2 months ago | 
onclive.com | Thomas W. LeBlanc |Thomas Leblanc |James Blachly |Aaron Goldberg |Rami D. Komrokji |Gabe Mannis | +1 more
Opinion Video February 11, 2025 Author(s): , Panelists discuss preclinical findings on the potential role of menin inhibitors in relapsed/refractory T-cell acute lymphoblastic leukemia (R/R T-ALL), the implications of p-MEF2C as a biomarker for reshaping the therapeutic landscape and integrating menin inhibitors such as revumenib into clinical practice, and what they anticipate learning from the upcoming presentation on menin inhibitor resistance, highlighting the role of MEN1 mutations in...
-
2 months ago | 
onclive.com | Thomas W. LeBlanc |Thomas Leblanc |James Blachly |Aaron Goldberg |Rami D. Komrokji |Gabe Mannis | +1 more
Opinion Video February 5, 2025 Author(s): , Panelists discuss the interim phase 1a results from KOMET-007 in newly diagnosed NPM1-mutated or KMT2A-rearranged AML, the potential role of ziftomenib combined with 7 plus 3 chemotherapy in standard induction therapy for high-risk acute monocytic leukemia (AML) patients with these mutations, preclinical findings on the combination of ziftomenib and selinexor in NPM1-mutant AML, and the mechanistic synergy between these therapies, exploring their...
-
2 months ago | 
onclive.com | Thomas W. LeBlanc |Thomas Leblanc |James Blachly |Aaron Goldberg |Rami D. Komrokji |Gabe Mannis | +1 more
OpinionVideoJanuary 29, 2025Author(s):,Panelists discuss the role of minimal residual disease (MRD) testing in acute monocytic leukemia (AML), key findings from the Australasian Leukaemia and Lymphoma Group (ALLG) AMLM26 INTERCEPT study on revumenib, and how the efficacy of revumenib in achieving MRD negativity in NPM1-mutated AML informs future MRD-guided treatment strategies, including the potential integration of menin inhibitors into standard AML relapse prevention protocols.
-
Jan 22, 2025 | 
onclive.com | Thomas W. LeBlanc |Thomas Leblanc |James Blachly |Aaron Goldberg |Rami D. Komrokji |Gabe Mannis | +1 more
OpinionVideoJanuary 22, 2025Author(s):,Panelists discuss the data updates from the AUGMENT-101 trial, the potential of revumenib to reshape the treatment landscape for patients with heavily pretreated KMT2A-rearranged acute leukemia, including its observed objective response rate (ORR) and complete remission (CR)/ CR with partial recovery of peripheral blood counts (CRh) rate, and the clinical implications of revumenib in the context of bridging to stem cell transplantation.
-
Jan 22, 2025 | 
onclive.com | Thomas W. LeBlanc |Thomas Leblanc |James Blachly |Aaron Goldberg |Rami D. Komrokji |Gabe Mannis | +1 more
OpinionVideoJanuary 22, 2025Author(s):,Panelists discuss the most commonly seen adverse effects (AEs) in menin inhibitor treatment, strategies for managing and mitigating these AEs to optimize outcomes, and how they compare across approved and pipeline menin inhibitors, along with best practices for clinicians to manage differentiation syndrome, a critical safety concern.
-
Jan 10, 2025 | 
onclive.com | Thomas W. LeBlanc |Thomas Leblanc |James Blachly |Aaron Goldberg |Rami D. Komrokji |Gabe Mannis | +1 more
OpinionVideoJanuary 10, 2025Author(s):,Panelists discuss how treatment goals in the second- and third-line settings for relapsed/refractory acute monocytic leukemia (R/R AML) now focus more on disease control, quality of life, and prolonging survival, and explore the most significant unmet needs in R/R AML, particularly in addressing drug resistance and optimizing therapeutic strategies.
-
Jan 10, 2025 | onclive.com | Thomas W. LeBlanc |Thomas Leblanc |James Blachly |Aaron Goldberg |Rami D. Komrokji |Gabe Mannis | +1 more
OpinionVideoJanuary 10, 2025Author(s):,Panelists discuss how treatment goals in the second- and third-line settings for relapsed/refractory acute monocytic leukemia (R/R AML) now focus more on disease control, quality of life, and prolonging survival, and explore the most significant unmet needs in R/R AML, particularly in addressing drug resistance and optimizing therapeutic strategies.
-
Jan 10, 2025 | 
onclive.com | Thomas W. LeBlanc |Thomas Leblanc |James Blachly |Aaron Goldberg |Rami D. Komrokji |Michael J. Thirman | +1 more
OpinionVideoJanuary 10, 2025Author(s):,Panelists discuss the FDA approval of revumenib for relapsed/refractory acute leukemia (R/R AML) with KMT2A translocation, reviewing the eligible patient population and the mechanism of action of this menin inhibitor, while exploring key findings from the AUGMENT-101 trial and how this approval may impact treatment approaches in both the R/R and broader AML settings.
-
Jan 10, 2025 | onclive.com | Thomas W. LeBlanc |Thomas Leblanc |James Blachly |Aaron Goldberg |Rami D. Komrokji |Michael J. Thirman | +1 more
OpinionVideoJanuary 10, 2025Author(s):,Panelists discuss the FDA approval of revumenib for relapsed/refractory acute leukemia (R/R AML) with KMT2A translocation, reviewing the eligible patient population and the mechanism of action of this menin inhibitor, while exploring key findings from the AUGMENT-101 trial and how this approval may impact treatment approaches in both the R/R and broader AML settings.
-
Feb 12, 2024 | 
onlinelibrary.wiley.com | Keith W Pratz |Brian A. Jonas |Vinod Pullarkat |Michael J. Thirman |Jacqueline Garcia |Hartmut Döhner | +9 more
1 INTRODUCTION Acute myeloid leukemia (AML) is a heterogenous neoplasm characterized by proliferation of immature myeloid cells in bone marrow and peripheral blood, leading to failure of normal hematopoiesis.1 AML is the most common acute leukemia in adults, with a median age at diagnosis of 68 years.
